Skip to content

Dinutuximab beta

Unituxin, Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron) (dinutuximab) is an antibody pharmaceutical. Dinutuximab was first approved as Unituxin on 2017-05-08. It is used to treat neuroblastoma in the USA. It has been approved in Europe to treat neuroblastoma.
Trade Name Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron)
Common Name Dinutuximab beta
Indication neuroblastoma
Drug Class Monoclonal antibodies: chimeric, tumors as target
Dinutuximab beta
Get full access now